|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bausch Health Companies, formerly known as Valeant Pharmaceutical International Inc., began trading under its new name today. CEO Joseph Papa discusses the new name and what other changes were made in an exclusive interview.
Eckert stopped by Fortune to talk about her "real launch" of Sprout's Addyi after getting it back from Valeant Pharmaceuticals.
Moody's Investors Service ("Moody's") assigned a Ba2 rating to the new senior secured note offering of Bausch Health Companies Inc. ("Bausch Health"), and a B3 rating to the new senior unsecured note offering of Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International), guaranteed by Bausch Health. There are no changes to Bausch Health's other ratings including the B2 Corporate Family Rating, the B2-PD Probability of Default Rating, the Ba2 senior secured rating, B3 senior unsecured rating and SGL-1 Speculative Grade Liquidity Rating. The transaction is credit positive because it will extend Bausch Health's debt maturities.
Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...
BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. "Eye care professionals have routinely stressed the need to have a readily available contact lens that addresses both presbyopia and astigmatism, underscoring the critical vision needs of this growing patient population," said Joe Gordon, U.S. president, Bausch + Lomb.
Moody's Investors Service ("Moody's") upgraded the ratings of Bausch Health Companies Inc. ("Bausch Health") including the Corporate Family Rating to B2 from B3, the Probability of Default Rating to B2-PD from B3-PD, the senior secured rating to Ba2 from Ba3 and the senior unsecured rating to B3 from Caa1. "The upgrade reflects continued progress in Bausch Health's turnaround including organic growth in major business lines, resolution of the Xifaxan patent challenge, and Moody's expectation for continued debt reduction," stated Michael Levesque, Moody's Senior Vice President.
LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne.
LAVAL, Quebec, Oct. 11, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018. In the studies, ALTRENO Lotion was shown to have significantly greater efficacy compared to vehicle in achieving treatment success, which was defined as at least a two-grade improvement from baseline in a global severity by Evaluator Global Severity Score (EGSS) and 'clear' or 'almost clear' skin.
Bill Ackman has seen better days. In October 2018, CNBC reported that Ackman's Pershing Square Capital made a$900 million bet on Starbucks. It was reported in February 2018, Ackman exited his entire $1-billion short bet against Herbalife. The fund faced a wave of redemption from institutional investors like the Blackstone Group and many asset managers like JP Morgan are no longer recommending it to clients, reported the Wall Street Journal in April.
Moody's Investors Service ("Moody's") affirmed certain ratings of Bausch Health Companies Inc. ("Bausch") and its subsidiaries, and revised the rating outlook to positive from stable. In addition, Moody's upgraded Bausch's Speculative Grade Liquidity Rating to SGL-1 from SGL-2.
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
PDUFA Date Set for February 25, 2019 LAVAL, Quebec , July 9, 2018 /PRNewswire/ -- – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, ...
On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
Salix Sales Force to Begin Promoting LUCEMYRA to Primary Care and Pain Management Physicians LUCEMYRA is the First and Only Non-Opioid Medication Approved for Mitigation of Opioid Withdrawal Symptoms LOUISVILLE, ...